Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $106 from $113 and keeps an Equal Weight rating on the ...

Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...

Finding it hard to breathe when you lay down is medically called orthopnea. Find a list of potential causes to help narrow down your overall risk here.

The S&P 500 added 0.7% on Tuesday, Feb. 4, as investors evaluated developments on U.S. tariffs, labor market data, and the latest earnings news.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

The Nasdaq Composite and S&P 500 advanced on Tuesday, driven by a sharp rally in Palantir shares, as investors assessed the latest global trade developments. The tech-heavy Nasdaq climbed 1.2%, while ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Palantir Technologies shares hit a record high as the company benefited from demand for its artificial intelligence software. U.S. equities were higher at midday, boosted by tech shares. The Nasdaq ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...